Search hospitals > Maine > Scarborough
Maine Children's Cancer Program
Claim this profileScarborough, Maine 04074
Global Leader in Leukemia
Global Leader in Tumors
Conducts research for Lymphoblastic Leukemia-Lymphoma
Conducts research for Lymphoma
Conducts research for Sarcoma
130 reported clinical trials
6 medical researchers
Summary
Maine Children's Cancer Program is a medical facility located in Scarborough, Maine. This center is recognized for care of Leukemia, Tumors, Lymphoblastic Leukemia-Lymphoma, Lymphoma, Sarcoma and other specialties. Maine Children's Cancer Program is involved with conducting 130 clinical trials across 269 conditions. There are 6 research doctors associated with this hospital, such as Eric C. Larsen, Aaron R. Weiss, Stanley Chaleff, MD, and Roger C. Inhorn.Area of expertise
1Leukemia
Global LeaderStage II
t(8;21)(q22;q22) positive
t(16;16)(p13;q22) positive
2Tumors
Global LeaderStage IV
Stage I
Stage II
Top PIs
Eric C. LarsenMaine Children's Cancer Program6 years of reported clinical research
Studies Lymphoma
Studies Leukemia
24 reported clinical trials
67 drugs studied
Aaron R. WeissMaine Children's Cancer Program3 years of reported clinical research
Studies Tumors
Studies Rhabdomyosarcoma
9 reported clinical trials
27 drugs studied
Stanley Chaleff, MDMaine Children's Cancer Program4 years of reported clinical research
Studies Brain Tumor
Studies Low Grade Glioma
6 reported clinical trials
14 drugs studied
Roger C. InhornWaldo County General Hospital8 years of reported clinical research
Studies Multiple Myeloma
Studies Solid Tumors
4 reported clinical trials
45 drugs studied
Clinical Trials running at Maine Children's Cancer Program
Rhabdomyosarcoma
Acute Lymphoblastic Leukemia
Brain Tumor
Osteosarcoma
Germ Cell Tumors
Lymphoma
Leukemia
Astrocytoma
Non-Hodgkin's Lymphoma
Tumors
Combination Chemotherapy
for Rhabdomyosarcoma
This study is evaluating whether a combination of chemotherapy drugs is more effective than a single chemotherapy drug for treating rhabdomyosarcoma.
Recruiting2 awards Phase 35 criteria
Chemotherapy
for Rhabdomyosarcoma
Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy using treatment with 24 weeks of vincristine and dactinomycin (VA) and examines the use of centralized molecular risk stratification in the treatment of rhabdomyosarcoma. Another aim of the study it to find out how well patients with low risk rhabdomyosarcoma (LR-RMS) respond to standard chemotherapy when patients with VLR-RMS and patients who have rhabdomyosarcoma with DNA mutations get separate treatment. Finally, this study examines the effect of therapy intensification in patients who have RMS cancer with DNA mutations to see if their outcomes can be improved.
Recruiting2 awards Phase 3
Genetic Testing-Directed Therapy
for Pediatric Cancer
This study is evaluating whether genetic testing may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Recruiting1 award Phase 214 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Maine Children's Cancer Program?
Maine Children's Cancer Program is a medical facility located in Scarborough, Maine. This center is recognized for care of Leukemia, Tumors, Lymphoblastic Leukemia-Lymphoma, Lymphoma, Sarcoma and other specialties. Maine Children's Cancer Program is involved with conducting 130 clinical trials across 269 conditions. There are 6 research doctors associated with this hospital, such as Eric C. Larsen, Aaron R. Weiss, Stanley Chaleff, MD, and Roger C. Inhorn.